Introduction of Anti-Small Molecules Hybridoma Development Services

The researchers at Creative Biolabs possess extensive expertise in anti-small molecule hybridoma development. We are highly confident in our proficiency and success rate, offering guaranteed positive clones as part of our service assurance. Our commitment at Creative Biolabs is to support the realization of your project's potential by delivering a comprehensive hybridoma development project plan. Leveraging our passion and expertise, we have formulated a range of antibodies targeting small molecules and heavy metal compounds. We trust that our technical services and products will provide you with convenience. We eagerly anticipate crafting a bespoke hybridoma development strategy tailored to your specific needs.

Fig.1 Comparing the size of small molecules and mAb.

Anti-Small Molecule Antibody Application

Small molecule-specific antibodies find extensive utility across diverse domains such as environmental surveillance and food safety, encompassing a spectrum of compounds like antibiotics, pesticides, toxins, pharmaceuticals, chemicals, lipids, vitamins, and amino acids. Typically, these molecules are detectable through physicochemical methods like chromatography or chromatography-mass spectrometry coupling, which necessitate costly materials and proficient personnel with expertise spanning biology and chemistry. In contrast, anti-small molecule antibodies offer an economical and highly sensitive means for detecting, visualizing, and quantifying these compounds.

• Detection of Small Molecule Biomarkers: Utilizing IHC or ELISA for detecting metabolites of amino acids, saccharides, lipids, steroids, nucleotides, and other small molecules.
• Applications in Food Safety and Environmental Diagnostics: Rapid ELISA detection methods for identifying toxins, pollutants, drug residues, and pesticide residues in food and environmental samples.
• Evaluation of Small Molecule Drug Availability: Assessing the penetration of drugs into tumor tissues via IHC or examining the ability of drug compounds to traverse the blood-brain barrier using IF or ELISA.

Moreover, anti-small molecule antibodies are rapidly emerging as a focal point in therapeutic endeavors, potentially providing an alternative avenue to antibody-drug conjugate (ADC) utilization. These antibodies have the potential to precisely target and deliver payloads to specific sites of action.

There are also some challenges awaiting. Small molecules typically lack immunogenicity primarily owing to their diminutive size, rendering them suboptimal as immunogens. Rendering small molecules immunogenic requires their conjugation to a carrier molecule like KLH, BSA, OVA, or CGG. However, linking the small molecule to the carrier protein and thereafter inducing the preferred immune reaction specific to the small molecule as opposed to the carrier protein or linker might be a big challenge.

Our Methodology for Hybridoma Development Targeting Small Molecules

Creative Biolabs suggests assessing various immunogenic factors of the small molecule, such as its chemical structure, conjugation techniques, cross-linking with the protein carrier, orientation of the hapten on the carrier protein, and types of linkers employed. Additionally, antigen presentation should replicate the orientation observed in the assay. We offer tailored immunization strategies to enhance the immune response against the small molecule, incorporating adjuvants, immunization techniques, and schedules.

• The selected carrier must possess immunogenicity and an ample supply of amino acids with reactive side chains for small molecule conjugation. Additionally, the carrier's origin species should differ from that of the immunized animal.
• The coupling strategy is determined by the available reactive sites on both the small molecule and the carrier, as well as the desired orientation of the conjugate.
• The density of haptens in the conjugate impacts the immune response. The optimal density is contingent upon the intended application and the molecule's structure.
• The length of the spacer is crucial for minimizing steric hindrance and enhancing the immunogenicity of the conjugate.

Tailor Your Own Small Molecule Hybridoma

Creative Biolabs offers personalized services for developing custom anti-small molecule monoclonal antibodies (mAbs) using hybridoma technology. Additionally, we provide competitively ELISA-validated hapten-carrier conjugates and antibodies.

• Customized antigen design strategies are available here. Various factors are taken into account during antigen design, including carrier selection, conjugation approach, hapten-carrier density, and spacer length.
• Comprehensive quality assurance measures, deliverables, and decision points are incorporated into the project, ensuring transparency, minimal risk, and deferred costs at the conclusion of each phase.
• Upon completion of the study, clients are provided with complete ownership of the hybridoma responsible for antibody production.
• Sophisticated chemical synthesis and conjugation techniques are employed.
• Quick turnaround times are guaranteed.

FAQ

1. Q1. Should the small molecules we provide be conjugated to a carrier protein?

   A: Creative Biolabs will initially assess the feasibility of coupling the small molecule structure. Depending on the requirements, different carrier proteins such as BSA, KLH, and OVA will then be employed for conjugation, which will subsequently be used for immunization.

2. Q2. What is the success rate of our small molecule hybridoma development process?

   A: The success rate of our small molecule hybridoma development process hinges on attaining a sufficiently high immune titer during the immunization stage. If the immune response proves suboptimal, we will modify the immunization protocol by increasing the dose or altering the adjuvant. With these adjustments, the success rate of our small molecule hybridoma development can reach 90%.

3. Q3. What will small molecule hybridoma development services in Creative Biolabs ultimately deliver?

   A: Our small molecule hybridoma development service will ultimately provide the customer with 1-3 positive cell lines, 1-3 mg of antibody, a comprehensive report, and the remaining antigens.

Leveraging our interdisciplinary proficiency in chemistry and biology ensures the creation and synthesis of optimal small molecule-carrier conjugates. As trailblazers in antibody development, Creative Biolabs is poised to produce anti-small molecule hybridomas and facilitate Bulk Antibody Production for clients globally. For further details, please contact us.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.